Consensus-Phenotype Integration of Transcriptomic and Metabolomic Data Implies a Role for Metabolism in the Chemosensitivity of Tumour Cells

Using transcriptomic and metabolomic measurements from the NCI60 cell line panel, together with a novel approach to integration of molecular profile data, we show that the biochemical pathways associated with tumour cell chemosensitivity to platinum-based drugs are highly coincident, i.e. they describe a consensus phenotype. Direct integration of metabolome and transcriptome data at the point of pathway analysis improved the detection of consensus pathways by 76%, and revealed associations between platinum sensitivity and several metabolic pathways that were not visible from transcriptome analysis alone. These pathways included the TCA cycle and pyruvate metabolism, lipoprotein uptake and nucleotide synthesis by both salvage and de novo pathways. Extending the approach across a wide panel of chemotherapeutics, we confirmed the specificity of the metabolic pathway associations to platinum sensitivity. We conclude that metabolic phenotyping could play a role in predicting response to platinum chemotherapy and that consensus-phenotype integration of molecular profiling data is a powerful and versatile tool for both biomarker discovery and for exploring the complex relationships between biological pathways and drug response.

[1]  P. G. Wells,et al.  Base excision repair of reactive oxygen species–initiated 7,8-dihydro-8-oxo-2′-deoxyguanosine inhibits the cytotoxicity of platinum anticancer drugs , 2009, Molecular Cancer Therapeutics.

[2]  G. Church,et al.  Systematic determination of genetic network architecture , 1999, Nature Genetics.

[3]  M. Hirai,et al.  Integration of transcriptomics and metabolomics for understanding of global responses to nutritional stresses in Arabidopsis thaliana. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[4]  Ralf Herwig,et al.  ConsensusPathDB—a database for integrating human functional interaction networks , 2008, Nucleic Acids Res..

[5]  R. Deberardinis,et al.  Beyond aerobic glycolysis: Transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis , 2007, Proceedings of the National Academy of Sciences.

[6]  Daniel Eriksson,et al.  Data integration in plant biology: the O2PLS method for combined modeling of transcript and metabolite data. , 2007, The Plant journal : for cell and molecular biology.

[7]  D. Spitz,et al.  2-Deoxy-D-glucose combined with cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cells. , 2007, Cancer research.

[8]  Ben van Ommen,et al.  Toxicogenomics of bromobenzene hepatotoxicity: a combined transcriptomics and proteomics approach. , 2003, Biochemical pharmacology.

[9]  Ben van Ommen,et al.  Profiles of Metabolites and Gene Expression in Rats with Chemically Induced Hepatic Necrosis , 2005, Toxicologic pathology.

[10]  Anil Potti,et al.  A genomic approach to identify molecular pathways associated with chemotherapy resistance , 2008, Molecular Cancer Therapeutics.

[11]  J. Essigmann,et al.  Mechanisms of resistance to cisplatin. , 2001, Mutation research.

[12]  Michael Darsow,et al.  ChEBI: a database and ontology for chemical entities of biological interest , 2007, Nucleic Acids Res..

[13]  P. Morin,et al.  Molecular mechanisms of platinum resistance: still searching for the Achilles' heel. , 2004, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[14]  D. Botstein,et al.  A gene expression database for the molecular pharmacology of cancer , 2000, Nature Genetics.

[15]  Cathy H. Wu,et al.  UniProt: the Universal Protein knowledgebase , 2004, Nucleic Acids Res..

[16]  B. Palsson,et al.  The model organism as a system: integrating 'omics' data sets , 2006, Nature Reviews Molecular Cell Biology.

[17]  Yves Gibon,et al.  Integration of metabolite with transcript and enzyme activity profiling during diurnal cycles in Arabidopsis rosettes , 2006, Genome Biology.

[18]  M. Ashburner,et al.  Gene Ontology: tool for the unification of biology , 2000, Nature Genetics.

[19]  H. Keun,et al.  Serum Molecular Signatures of Weight Change during Early Breast Cancer Chemotherapy , 2009, Clinical Cancer Research.

[20]  C. Boschek,et al.  Pyruvate kinase type M2 and its role in tumor growth and spreading. , 2005, Seminars in cancer biology.

[21]  J. Lindon,et al.  Pharmaco-metabonomic phenotyping and personalized drug treatment , 2006, Nature.

[22]  Nello Cristianini,et al.  A statistical framework for genomic data fusion , 2004, Bioinform..

[23]  L. Gianni,et al.  Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity , 2004, Pharmacological Reviews.

[24]  John C Lindon,et al.  Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism , 2009, Proceedings of the National Academy of Sciences.

[25]  Jae K. Lee,et al.  Concordant gene expression signatures predict clinical outcomes of cancer patients undergoing systemic therapy. , 2009, Cancer research.

[26]  David S. Wishart,et al.  MSEA: a web-based tool to identify biologically meaningful patterns in quantitative metabolomic data , 2010, Nucleic Acids Res..

[27]  Jae K. Lee,et al.  Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study , 2007, Molecular Cancer Therapeutics.

[28]  B. Daignan-Fornier,et al.  Dysregulation of Purine Nucleotide Biosynthesis Pathways Modulates Cisplatin Cytotoxicity in Saccharomyces cerevisiae , 2008, Molecular Pharmacology.

[29]  Jerry Goodisman,et al.  Analysis of cytotoxicities of platinum compounds , 2005, Cancer Chemotherapy and Pharmacology.

[30]  P. Karp,et al.  Computational prediction of human metabolic pathways from the complete human genome , 2004, Genome Biology.

[31]  Frederick P Roth,et al.  Metabolomic Identification of Novel Biomarkers of Myocardial Ischemia , 2005, Circulation.

[32]  Z. Hall.  Cancer , 1906, The Hospital.

[33]  John T. Wei,et al.  Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression , 2009, Nature.

[34]  V. Raman,et al.  Choline kinase overexpression increases invasiveness and drug resistance of human breast cancer cells , 2010, NMR in biomedicine.

[35]  M. Hirai,et al.  Elucidation of Gene-to-Gene and Metabolite-to-Gene Networks in Arabidopsis by Integration of Metabolomics and Transcriptomics* , 2005, Journal of Biological Chemistry.

[36]  Dominique Gauguier,et al.  Direct quantitative trait locus mapping of mammalian metabolic phenotypes in diabetic and normoglycemic rat models , 2007, Nature Genetics.

[37]  Elaine Holmes,et al.  Systems toxicology: integrated genomic, proteomic and metabonomic analysis of methapyrilene induced hepatotoxicity in the rat. , 2006, Journal of proteome research.

[38]  F. Wright,et al.  Use of Pharmaco‐Metabonomics for Early Prediction of Acetaminophen‐Induced Hepatotoxicity in Humans , 2010, Clinical pharmacology and therapeutics.

[39]  Olga G. Troyanskaya,et al.  Coordinated Concentration Changes of Transcripts and Metabolites in Saccharomyces cerevisiae , 2009, PLoS Comput. Biol..

[40]  Kenneth H. Buetow,et al.  PID: the Pathway Interaction Database , 2008, Nucleic Acids Res..

[41]  M. Rantalainen,et al.  Statistically integrated metabonomic-proteomic studies on a human prostate cancer xenograft model in mice. , 2006, Journal of proteome research.

[42]  Timothy M. D. Ebbels,et al.  Bioinformatic methods in NMR-based metabolic profiling , 2009 .

[43]  S. Vitols,et al.  Elevated uptake of low density lipoprotein by drug resistant human leukemic cell lines. , 2002, Biochemical pharmacology.

[44]  Z. Siddik,et al.  Cisplatin: mode of cytotoxic action and molecular basis of resistance , 2003, Oncogene.

[45]  R. Ladner,et al.  Small interfering RNA-mediated suppression of dUTPase sensitizes cancer cell lines to thymidylate synthase inhibition. , 2004, Molecular pharmacology.

[46]  M. Orešič,et al.  Pathways to the analysis of microarray data. , 2005, Trends in biotechnology.

[47]  William C Reinhold,et al.  Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel , 2006, Molecular Cancer Therapeutics.

[48]  K. Hande,et al.  Etoposide: four decades of development of a topoisomerase II inhibitor. , 1998, European journal of cancer.

[49]  Hiroyuki Ogata,et al.  KEGG: Kyoto Encyclopedia of Genes and Genomes , 1999, Nucleic Acids Res..

[50]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[51]  Lincoln Stein,et al.  Reactome: a knowledgebase of biological pathways , 2004, Nucleic Acids Res..

[52]  D. Sabatini,et al.  Cancer Cell Metabolism: Warburg and Beyond , 2008, Cell.

[53]  T. Ideker,et al.  Network-based classification of breast cancer metastasis , 2007, Molecular systems biology.